COVID-19 Updates
Conference Coverage
SGLT2 inhibitors: No benefit or harm in hospitalized COVID-19
“I think the most important take-home message here is that the use of these medications appears to be safe even in really acutely ill hospitalized...
Latest News
New Moderna vaccine to work against recent COVID variant
The FDA is expected to approve the new Moderna shot by early October.
Feature
Q&A: What to know about the new BA 2.86 COVID variant
BA 2.86 is a subvariant of Omicron, but according to reports from the CDC, the strain has many more mutations than the ones that came before it....
From the Journals
Severe COVID may cause long-term cellular changes: Study
This study shows that after severe COVID, the immune system remains in ‘emergency mode’ and in a heightened state of inflammation.
From the Journals
COVID may increase risk of high blood pressure
“Given the sheer number of people affected by COVID-19, compared to influenza, these statistics are alarming and suggest that many more patients...
Latest News
International rights group calls out United States for allowing hospitals to push millions into debt
About a third of U.S. adults with health care debt owed money for hospitalization.
From the Journals
Review supports continued mask-wearing in health care visits
Masks continue to lower the risk of catching the virus during medical visits.
Conference Coverage
Hyperbaric oxygen may improve heart function in long COVID
“We should open our minds to thinking about this treatment for another indication. That is the basis of precision medicine. We have this treatment...
Commentary
Clinical trials: Top priority for long COVID
Behavioral treatments including exercise, graded exercise therapy, and cognitive-behavioral therapy should not be trialed, let alone prioritized,...
Latest News
Long COVID hitting some states, minorities, women harder
The survey found that women, smokers, and those who had severe COVID-19 infections are most likely to have the disorder.
Conference Coverage
FREEDOM COVID: Full-dose anticoagulation cut mortality but missed primary endpoint
In an in-hospital anticoagulation trial, the primary COVID endpoint was missed but a survival benefit is observed.